|
1）Epstein AE, Dimarco JP, Ellenbogen KA, et al; American College of Cardiology/American Heart Association Task Force on Practice; American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm. 2008; 5: 934-55
|
|
|
|
2）Shiga T, Hagiwara N, Ogawa H, et al. Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era: results from the HIJAMI-II registry. Heart. 2009; 95: 216-20
|
|
|
|
|
|
3）Tanno K, Miyoshi F, Watanabe N, et al. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J. 2005; 69: 19-22
|
|
|
|
|
4）循環器病の診断と治療に関するガイドライン（2010年度合同研究班報告）．不整脈の非薬物治療ガイドライン（2011年改訂版）. 2011
|
|
|
|
|
|
5）Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008; 359: 1009-17
|
|
|
|
|
|
6）van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011; 57: 556-62
|
|
|
|
|
|
7）Gold MR, Theuns DA, Knight BP, et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2012; 23: 359-66
|
|
|
|
|
|
8）Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012; 367: 2275-83
|
|
|
|
|
|
9）Gasparini M, Proclemer A, Klersy C, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013; 309: 1903-11
|
|
|
|
|
|
10）Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA. 2011; 305: 43-9
|
|
|
|
|
|
11）Dillon KA, Szymkiewicz SJ, Kaib TE. Evaluation of the effectiveness of a wearable cardioverter defibrillator detection algorithm. J Electrocardiol. 2010; 43: 63-7
|
|
|
|
|
|
12）Klein HU, Goldenberg I, Moss AJ. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J. 2013; 34: 2230-42
|
|
|
|
|
|
13）Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010; 363: 36-44
|
|
|
|
|
|
14）Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol. 2012; 60: 1933-9
|
|
|
|
|
|
15）Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J. 2012; 163: 260-7 e3
|
|
|
|
|
|
16）Linde C, Abraham WT, Gold MR, et al; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008; 52: 1834-43
|
|
|
|
|
|
17）Thibault B, Harel F, Ducharme A, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex ＜120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation. 2013; 127: 873-81
|
|
|
|
|
|
18）Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361: 1329-38
|
|
|
|
|
|
19）Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010; 363: 2385-95
|
|
|
|
|
|
20）Wilton SB, Leung AA, Ghali WA, et al. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2011; 8: 1088-94
|
|
|
|
|
|
21）Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011; 8: 1469-75
|
|
|
|
|
|
22）Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011; 32: 2420-9
|
|
|
|
|
|
23）Brignole M, et al; ESC Committee for Practice Guidelines (CPG), Zamorano JL, et al; Document Reviewers, Kirchhof P, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013; 34: 2281-329
|
|
|
|
|
|
24）Thebault C, Donal E, Meunier C, et al. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012; 33: 2662-71
|
|
|
|
|
|
25）Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation. 2011; 123: 1159-66
|
|
|
|
|
|
26）Duckett SG, Ginks M, Shetty AK, et al. Invasive acute hemodynamic response to guide left ventricular lead implantation predicts chronic remodeling in patients undergoing cardiac resynchronization therapy. J Am Coll Cardiol. 2011; 58: 1128-36
|
|
|
|
|
|
27）Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012; 59: 1509-18
|
|
|
|
|
|
28）Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010; 122: 2660-8
|
|
|
|
|